CHRM4 and Alzheimer disease: Selective M4R PAMs have shown potential for managing neuropsychiatric symptoms associated with AD, such as agitation and aggression, with improved therapeutic margins for cholinergic adverse effects compared to less selective muscarinic receptor agonists [119].